Physician

Steven R Rousey, M.D.

According to 2025 Medicare claims, Steven Rousey, M.D. (NPI: 1427027119) practices hematology/oncology in the Minneapolis-St. Paul-Bloomington, MN-WI market, with the plurality of this provider's patient population coming from Carver, MN. This provider's primary affiliated billing organization is MINNESOTA ONCOLOGY HEMATOLOGY, PA (NPI: 1528035995; TIN: 411793418) and primary practice location at 55387-1753. Rousey is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Rousey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 323 traditional Medicare patients, billed 66,637 HCPCS/CPT codes, and received $1,729,872 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,855 prescription claims across 347 beneficiaries totaling $5,190,239 in drug costs, led by Ibrance (Palbociclib). DME data shows 71 claims. Open Payments data shows 20 records totaling $18,155. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $455,251 to $1,729,872. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,368,351 to $5,190,239. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	380	50,169	$455,251
2016	380	57,375	$579,583
2017	308	24,637	$520,276
2018	307	35,968	$619,668
2019	579	85,445	$1,227,364
2020	437	75,334	$950,778
2021	500	122,458	$1,322,528
2022	493	73,643	$1,490,742
2023	397	78,729	$1,524,660
2024	323	66,637	$1,729,872

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	164	1,014	$1,368,351
2016	190	1,211	$1,610,029
2017	202	1,386	$2,567,137
2018	194	1,449	$3,268,245
2019	234	1,335	$2,539,068
2020	258	1,522	$2,860,359
2021	289	1,584	$4,892,204
2022	360	1,793	$5,215,158
2023	369	1,701	$4,138,287
2024	347	1,855	$5,190,239

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	39	$1,013
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	38	$2,273
2020	N/R	N/R	N/R
2021	N/R	22	$36,128
2022	N/R	25	$40,200
2023	N/R	36	$41,957
2024	N/R	71	$43,813

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	37	212	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	191	389	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	74	80	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	32	32	$13
36415	Insertion of needle into vein for collection of blood sample	38	104	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	44	1,232	$676,747
Brukinsa	Zanubrutinib	43	1,290	$632,438
Calquence	Acalabrutinib Maleate	39	1,170	$579,282
Lenalidomide	Lenalidomide	40	1,113	$528,493
Revlimid	Lenalidomide	30	792	$417,130

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$37,078
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	14	$4,615
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	18	$1,270
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$425
E1392	Portable oxygen concentrator, rental	Y	N/R	12	$425

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$16	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	19	$18,139	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Steven R. Rousey, M.D.?

Tedicare shows public-source Medicare data for Steven R. Rousey, M.D. (NPI 1427027119), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Steven R. Rousey, M.D. have ACO affiliation data?

Steven R. Rousey, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Steven R. Rousey, M.D.?

Steven R. Rousey, M.D. is linked to MINNESOTA ONCOLOGY HEMATOLOGY, PA (billing NPI 1528035995) in the available physician profile data.

Does Steven R. Rousey, M.D. have Open Payments data?

Steven R. Rousey, M.D. has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.